Thursday November 30

Agenda Day 1

Dr Peter Hotez
Dr James Crowe

Human Vaccine Project: How much of the immune response do we understand? Deciphering the human immunome for a better vaccine design

  • How have technological advances in next-generation DNA sequencing offered ways to probe the human immune system?
  • Results so far on the Human Immunome that could lead to acceleration of vaccine development
  • Working toward a complete catalogue of expressed human immune receptors
  • Challenges in interpreting the vast amount of data into meaningful information
Dr Darrick Carter

What can we learn from vaccine development for infectious diseases that can be applied to cancer and vice versa?

  • Bridging infectious disease vaccines with cancer immunotherapy
  • Technologies that are applicable to both including RNA vaccines
  • How to stimulate both humoral and cell-mediated immunity that are likely paramount for successful cancer immunotherapeutics
  • Understanding infectious vaccine approaches and immunological responses to strengthen cancer immunotherapeutic strategies

NEW: Speed networking – Break the ice with your peers!

Allowing conference delegates to meet each other for a short space of time and exchange business cards. A unique feature guaranteeing heightened networking for all participants

Morning Networking Break

Immune Characterisation Techniques

New immunotherapy trends

Investment Perspectives

Infectious Diseases

The Human Vaccine Project’s first clinical trial: Understanding the rules of lifelong immunological protection

  • The importance of looking at all aspects of immune response and integrating this data to get an accurate reflection of response to vaccination
  • What distinguishes the 30% of people who have a good response after a single dose of Hep B vaccine
  • Results from initial study assessing immune responses of 10 healthy adults (ages 40-80) to a licensed hepatitis B vaccine, expansion into larger numbers and demographics
  • Outlook for 2018 and beyond:  projects looking at HPV vaccination – challenges to overcome

Personalized cancer vaccines that target patients-specific mutations: Platforms amenable for neoantigen vaccination

  • Strategies for target antigen identification and validation 
  • Personalized vaccines-specific considerations in adjuvant selection
  • Challenges in clinical studies, i.e., patient selection, dose selection, efficacy determination and regulatory paths
Infectious Diseases

Lymph node fine needle aspirates to reveal correlates for immunization-induced neutralizing antibodies

  • The central role of the germinal center response in generating neutralizing antibodies after HIV Env trimer immunization.
  • The importance of immunization route.
  • Lymph node fine needle aspirates can be used to analyze germinal centers in humans after immunization.

The identification of tumor-host interactions that propagate an anti-tumor immune response

  • A deeper understanding of tumor-host interaction is essential for the development of effective immunotherapies
  • Designing successful clinical trials to identify responders and non-responders
  • Using the insight gained from clinical trials to identify which patients will benefit from which drug combinations
Funding and Partnerships

Investment Banking Panel: Status of the US vaccine & immunotherapy market

  • Health of the US vaccine and immunotherapy market
  • What’s needed to offer private financing or public offerings
  • What do investors currently have an appetite for?
Infectious Diseases

Early innate immune responses to Hep B vaccination using single cell RNA sequencing approaches

  • Using single cell transcriptomic analysis to more accurately define and evaluate vaccine responses, with Hep B as an example
  • What’s happening immediately after vaccination in the primary response?
  • Unique data challenges in integrating meaningful analysis into better vaccine design
  • Application of machine learning methods – can we predict how our immune system responds?

Insights into combination studies across various tumour types

  • The rational for pursuing combination therapy, the number of combinations currently being pursued
  • Examples of current combinations with TECENTRIQ and other partner molecules
  • Challenges associated with developing combination clinical trial studies – should we change how these trials are designed?

Networking Lunch & Poster Session

Respiratory & Emerging Diseases

Infectious Diseases

Clinical results of a novel oral Norovirus vaccine

  • Intestinal immunity may be necessary for protection against norovirus infection
  •  Oral immunization induces a robust mucosal memory and effector antibody response

Advanced immune characterization using RNA enables biomarker discovery in limiting and diverse samples

  • Highlight approaches to characterize the tumor microenvironment and current hurdles
  • Introduction of new technology which reveals immune cell composition present in the tumor, elucidates activated immune-escape pathways, and measures mutational burden to characterize tumor foreignness, all from a single RNA sample
  • Validation data and case study overview
Funding and Partnerships

Corporate Venture Panel: Unique investment strategies and investing in platform technologies

  • What are corporate venture firms looking for? What is the best point of entry?
  • What is the nature of the terms and conditions; the unique structure of each CVC firm
  • How closely do we work with our parent companies?
  • Investing in early-stage companies and investment timelines
  • Differences in balance between strategic focus and financial focus.
Infectious Diseases

Nasal vaccination for respiratory infections

  • Introduction to technology platform; mobilizing the immune system in ways conventional vaccines cannot
  • Key advantages of nasal vaccination
  • NasoVAX seasonal influenza clinical program updates
Infectious Diseases

Progress toward developing a preventive MERS-CoV vaccine

  • Since it was first isolated in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has caused severe acute lower respiratory disease in more than 2000 people across 27 countries and killed 35% of those it has infected.
  • The high case fatality ratio, broad geographic distribution and absence of a licensed therapy or vaccine has created an imperative for an effective public health countermeasure to MERS
  • Preliminary findings from our first-in-human phase 1 trial of a MERS CoV consensus MERS Spike DNA vaccine are presented and placed in the context of the larger efforts to develop a preventive vaccine for MERS CoV.

Next generation biomarkers for the era of precision cancer immunotherapy

  • “Empiric” and “science-driven” approaches to clinical experimentation are synergistic, and enable iterative learning
  • Novel biomarker tools are needed to enable more accurate interpretation of clinical results from combination I-O clinical trials.
  • Precision immuno-oncology: Biomarkers that describe fundamental parameters of tumor immunobiology are needed to triage patients to the appropriate combination therapies.
  • Implications:
    • Clinical trial design (enrichment, umbrella, basket)
    • Diagnostics: Acceleration of novel biomarkers
    • Regulatory:  Accelerated approval for biomarker-defined populations; complementary diagnostics; tumor-agnostic labeling
Funding and Partnerships

A Regulatory Perspective --- Clinical Considerations for Novel Immunotherapies

  • Brief overview of approval processes
  • Review of cell therapies including; adoptive T-cell’s, CAR- T cells, TCRs
  • A closer look at cancer vaccines and neoantigens
Infectious Diseases

ELISpot and FluoroSpot in vaccine research, development, and evaluation

  • Measure T-cell and B-cell responses at the single cell level
  • Virus cross-reactivity in Influenza
  • Ferret IFN-gamma ELISpot

Increasing the potency of DNA-based immunotherapies using PolyStart peptide expression system

  • PolyStart is a unique plasmid DNA construct that expresses four or more peptides for each molecule of mRNA, rather than the dogmatic one DNA = one RNA = one protein
  • How PolyStart can increase the efficiency with which target cells can be identified and elminated
  • Applications in immuno-oncology and potential for use in infectious disease
Infectious Diseases

Optimized presentation of antigens using enveloped Virus Like Particles

  • Use of enveloped virus-like particles (eVLPs) for inducing neutralizing antibodies against CMV
  • eVLP expression of multiple antigens for use in immunotherapy
  • Mechanisms responsible for eVLP-based vaccine potency
Funding and Partnerships

Innovative finance mechanisms for funding vaccine procurement

  • What financial mechanisms does GAVI use to ensure they can sustain investment in vaccines 
  • Tools used to incentivize certain types of vaccine development
    • E.g. Advanced market commitment to pneumococcal vaccines
  • The vaccine investment strategy process
    • Used to inform GAVI which vaccines they will invest in from 2020
    • GAVI’s view on the landscape of vaccine development

Networking Break

Infectious Diseases

Is it time to start considering antibodies as an alternative to vaccines?

  • Synagis® (palivizumab) is the only monoclonal antibody (MAb) currently marketed for prevention of an infectious disease
  • Advances in biologics technology has allowed the development of a highly potent MAb that is being investigated as a vaccine surrogate to protect all infants from RSV disease
  • Are there other diseases, for which vaccine development has been difficult, where MAbs might fill the void?

Mechanisms of action of Talimogene Laherparepvec: From Bench to Bedside

  • Preclinical data and mechanism of action
  • Updates on clinical data in combination with checkpoint inhibitors
Funding and Partnerships

The application of machine learning methods to accelerate the development of vaccines and immunotherapies

  • Brief introduction to key machine learning techniques
  • Examples of where these techniques have already been applied in the development of vaccines.
  • The application of machine learning methods to the initial results of the HVP’s first clinical trial
  • Future outlook and scope of how this technology can help advance the field of vaccines and immunotherapy

Delivering multiple immunotherapies in a single construct; what makes WO-12 unique amongst oncolytic virotherapies?

  • WO-12 is an immuno-oncolytic virus engineered to replicate in cancer cells while delivering therapeutic transgenes that train the immune system to target the tumor
  • How does WO-12's interaction with TLR signalling pathways result in increased beneficial T-Cell responses while reducing the antibody response?
  • The importance of modifying the tumour micro-environment in eliciting good immunotherapeutic responses
  • Challenges to overcome in achieving systemic delivery
  • Outlook for beginning of human clinical trials in 2018
Infectious Diseases

Using 3D Cryo-electron microscopy technology to determine the structures of vaccine nanoparticles to enable better vaccine design

  • Using state of the art structural biology techniques to design nanoparticles that display conserved epitopes; influenza case study
  • The importance of conformational state in B-cell activation
  • Potential for use in other infectious diseases and immunotherapy
  • The future of immunogen design to elicit the required antibodies and the characterisation of therapeutic antibodies to boost immune response

The generation and modulation of immunogenic cell death using oncolytic viruses

  • What is immunogenic cell death? Mechanism and modulation by oncolytic viruses
  • Signalling pathways that regulate the tumor immunosuppressive milieu and their alteration
  • Cancer stem cells immunology and inhibition of tumor immune escape
  • Modulation of immunogenic cell death by combining oncolytic viruses with other therapies
Funding and Partnerships

Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor Amid Wealth

  • Today most of the poverty-related neglected diseases are found in G20 nations
  • The poor living among the wealthy account for this disease burden
  • This provides a key policy framework for new innovations to address the world's poverty-related neglected diseases
  • Examples in the context of Zika, and other emerging infections

Chair closing remarks of day one followed by drinks reception and Meet & Greet with key speakers

last published: 21/Nov/17 16:35 GMT